Bruker Corporation has announced significant advancements in mass spectrometry technology at the 73rd American Society for Mass Spectrometry (ASMS) Conference. The company unveiled the timsMetabo™ platform, which offers high-sensitivity analysis for small molecules, specifically targeting PFAS and environmental contaminants. Additionally, Bruker introduced the integration of RECIPE's ClinMass® and ClinDART® assay kits with its EVOQ® DART-TQ⁺ system, aimed at improving therapeutic drug monitoring (TDM) and drugs of abuse (DoA) analysis. These innovations are expected to enhance laboratory productivity by enabling high-throughput, chromatography-free workflows. Bruker plans to further develop solutions for forensic toxicology and emerging contaminants, underlining its commitment to addressing real-world analytical challenges.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。